182 related articles for article (PubMed ID: 21030882)
1. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.
Hayashi T; Chan M; Norton JT; Wu CC; Yao S; Cottam HB; Tawatao RI; Corr M; Carson DA; Daniels GA
Melanoma Res; 2011 Feb; 21(1):66-75. PubMed ID: 21030882
[TBL] [Abstract][Full Text] [Related]
2. Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.
Butchi NB; Du M; Peterson KE
Glia; 2010 Apr; 58(6):650-64. PubMed ID: 19998480
[TBL] [Abstract][Full Text] [Related]
3. Induction of oligoclonal CD8 T cell responses against pulmonary metastatic cancer by a phospholipid-conjugated TLR7 agonist.
Hosoya T; Sato-Kaneko F; Ahmadi A; Yao S; Lao F; Kitaura K; Matsutani T; Carson DA; Hayashi T
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6836-E6844. PubMed ID: 29967183
[TBL] [Abstract][Full Text] [Related]
4. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.
Koga-Yamakawa E; Murata M; Dovedi SJ; Wilkinson RW; Ota Y; Umehara H; Sugaru E; Hirose Y; Harada H; Jewsbury PJ; Yamamoto S; Robinson DT; Li CJ
Cancer Immunol Immunother; 2015 Oct; 64(10):1229-39. PubMed ID: 26091797
[TBL] [Abstract][Full Text] [Related]
5. A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
Wang X; Yu B; Cao B; Zhou J; Deng Y; Wang Z; Jin G
Int J Cancer; 2021 Jan; 148(2):437-447. PubMed ID: 32683685
[TBL] [Abstract][Full Text] [Related]
6. TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer.
Butterfield JSS; Biswas M; Shirley JL; Kumar SRP; Sherman A; Terhorst C; Ling C; Herzog RW
Hum Gene Ther Methods; 2019 Jun; 30(3):81-92. PubMed ID: 31140323
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates.
Chan M; Hayashi T; Kuy CS; Gray CS; Wu CC; Corr M; Wrasidlo W; Cottam HB; Carson DA
Bioconjug Chem; 2009 Jun; 20(6):1194-200. PubMed ID: 19445505
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of induced nitric oxide synthase enhances the anti-tumor effects on cancer immunotherapy using TLR7 agonist in mice.
Ito H; Ando T; Ogiso H; Arioka Y; Seishima M
Cancer Immunol Immunother; 2015 Apr; 64(4):429-36. PubMed ID: 25567751
[TBL] [Abstract][Full Text] [Related]
9. Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7.
Hayashi T; Cottam HB; Chan M; Jin G; Tawatao RI; Crain B; Ronacher L; Messer K; Carson DA; Corr M
Am J Physiol Regul Integr Comp Physiol; 2008 Jul; 295(1):R123-32. PubMed ID: 18480244
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 7 cooperates with IL-4 in activated B cells through antigen receptor or CD38 and induces class switch recombination and IgG1 production.
Tsukamoto Y; Nagai Y; Kariyone A; Shibata T; Kaisho T; Akira S; Miyake K; Takatsu K
Mol Immunol; 2009 Apr; 46(7):1278-88. PubMed ID: 19157556
[TBL] [Abstract][Full Text] [Related]
13. The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
Cho JH; Lee HJ; Ko HJ; Yoon BI; Choe J; Kim KC; Hahn TW; Han JA; Choi SS; Jung YM; Lee KH; Lee YS; Jung YJ
Oncotarget; 2017 Apr; 8(15):24932-24948. PubMed ID: 28212561
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects.
Crain B; Yao S; Keophilaone V; Promessi V; Kang M; Barberis A; Maj R; Mura E; Passini N; Holldack J; Ochoa R; Cottam HB; Carson DA; Hayashi T
Eur J Dermatol; 2013; 23(5):618-28. PubMed ID: 24225049
[TBL] [Abstract][Full Text] [Related]
15. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
Singh M; Khong H; Dai Z; Huang XF; Wargo JA; Cooper ZA; Vasilakos JP; Hwu P; Overwijk WW
J Immunol; 2014 Nov; 193(9):4722-31. PubMed ID: 25252955
[TBL] [Abstract][Full Text] [Related]
16. Treatment of autoimmune inflammation by a TLR7 ligand regulating the innate immune system.
Hayashi T; Yao S; Crain B; Chan M; Tawatao RI; Gray C; Vuong L; Lao F; Cottam HB; Carson DA; Corr M
PLoS One; 2012; 7(9):e45860. PubMed ID: 23029281
[TBL] [Abstract][Full Text] [Related]
17. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways.
Duechs MJ; Hahn C; Benediktus E; Werner-Klein M; Braun A; Hoymann HG; Gantner F; Erb KJ
Pulm Pharmacol Ther; 2011 Apr; 24(2):203-14. PubMed ID: 21195789
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 7 mediates early innate immune responses to malaria.
Baccarella A; Fontana MF; Chen EC; Kim CC
Infect Immun; 2013 Dec; 81(12):4431-42. PubMed ID: 24042114
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
20. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells.
Forward NA; Furlong SJ; Yang Y; Lin TJ; Hoskin DW
J Leukoc Biol; 2010 Jan; 87(1):117-25. PubMed ID: 19843574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
